Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

(2016) Venkat Reddy et al.   DRUG DISCOVERY TODAY

Features of Human CD3+CD20+T Cells

(2016) Elisabeth Schuh et al.   JOURNAL OF IMMUNOLOGY

Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis

(2015) Manjari Lahiri et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis

(2015) Dominic Borie et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

CD19 as a molecular target in CNS autoimmunity

(2014) Olaf Stüve et al.   ACTA NEUROPATHOLOGICA

The efficacy of novel B cell biologics as the future of SLE treatment: A review

(2014) Ameer Kamal et al.   AUTOIMMUNITY REVIEWS

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

(2014) Ludwig Kappos et al.   LANCET NEUROLOGY

Trial and error in clinical studies: lessons from ATAMS

(2014) Fred Lühder et al.   LANCET NEUROLOGY

The Charcot Lecture | Beating MS: A story of B cells, with twists and turns

(2014) Stephen L Hauser   Multiple Sclerosis Journal

Alemtuzumab: The advantages and challenges of a novel therapy in MS

(2014) T. Menge et al.   NEUROLOGY

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

(2014) Paul Emery et al.   PLoS One

CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination

(2014) Janet E. Holley et al.   Multiple Sclerosis and Related Disorders

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

(2013) Venkat Reddy et al.   ARTHRITIS RESEARCH & THERAPY

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

(2012) Robert A. Eisenberg et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

Helminth-induced CD19+CD23hi B cells modulate experimental allergic and autoimmune inflammation

(2010) Mark S. Wilson et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: Novel Function of B Cell-Activating Factor in the Induction of IL-10-Producing Regulatory B Cells

(2010) M. Yang et al.   JOURNAL OF IMMUNOLOGY

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM

New approaches of B-cell-directed therapy: beyond rituximab

(2009) Thomas Dörner et al.   CURRENT OPINION IN RHEUMATOLOGY

Helminth Antigens Modulate Immune Responses in Cells from Multiple Sclerosis Patients through TLR2-Dependent Mechanisms

(2009) J. Correale et al.   JOURNAL OF IMMUNOLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties

(2009) Moutih Rafei et al.   NATURE MEDICINE

Helminth infections associated with multiple sclerosis induce regulatory B cells

(2008) Jorge Correale et al.   ANNALS OF NEUROLOGY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE